Skip To Main Content
Patrick Duffy on Muck Rack

Patrick Duffy

As seen in: Amazon Web Services, IMDb, Daily Mail, Irish Daily Mail, Nature, The Guardian, PLOS, Associated Press: Press Releases, MDPI, U.S. News and World Report and
A California Oral and Maxillofacial Surgeon

Get in touch with Patrick

Contact Patrick, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Patrick Duffy’s Biography

Read Full Bio →

Patrick Duffy, DDS, MD, a board-certified oral and maxillofacial surgeon, cares for patients in Fremont, California. In preparation for his oral health career, he earned his doctor of dental surgery from the Columbia University School of Dental and Oral Surgery. While there, Dr. Patrick Duffy served as editor of the Columbia Dental Journal. Following his time at Columbia, he enrolled at the State University of New York Health Science Center, from which he achieved his doctor of medicine. He als…

Articles

20 Washington: An Icon Reborn

|
By Patrick Duffy
| IRK Magazine
The first thing people do when they arrive at 20 Washington is look up. Not because anyone tells them to. They simply do. They step beneath the monumental white portico, passing between soaring quartz-faced columns that seem to dissolve into the Minnesota sky. The noise of Washington Avenue begins to soften. Reflections ripple across the pools below. Vermont Verde marble catches the changing light, shifting from deep green to nearly black as clouds drift overhead.
Open in Who Shared Issue with article?

Sweet Land, Twenty Years Later

|
By Patrick Duffy
| IRK Magazine
There are films that age into nostalgia, and then there are films that deepen with time, quietly gathering new meaning as the world around them changes. SWEET LAND is one such film. On June 20, the Walker Cinema in Minneapolis welcomed a full house for the 20th-anniversary screening of Sweet Land, Ali Selim’s beloved 2006 independent film.
Open in Who Shared Issue with article?

Identification of cross-stage, cross-species malaria CD8 + T cell antigens

|
By Paulo Bettencourt, David Morrow Verified, Dhelio B. Pereira, Maya Aleshnick, Julie Mitchell, Nicholas Poulton, Christina Ntalla, Zezhou Zhao, Guilherme Maia, Marie Rose Schrimpf, Camila Costa, Annalisa Nicastri, Roxanne M. Gilbride, John B. Schell, Payton Kirtley, Gaurav D. Gaiha, Scott Hansen, Judy Lieberman, Ricardo Gazzinelli, Moussa Niangaly, John Woodford, Joel Goldberg, Klaus Früh, Patrick Duffy, Nicola Ternette, Brandon Wilder, Adrian Hill, Caroline Junqueira, Camila R. R. Barbosa, Luna B. de Lacerda, Cristopher Gomes, Lídia P. B. Cordeiro, Kadia Doumbia, Charles Arama, Gregório G. Almeida, Thalia F. Hart, Derek Haumpy, Beatriz C. Medeiros-Rodrigues, Lis R. V. Antonelli
| Nature Verified
Abstract A major limitation on the development of a malaria vaccine is the lack of validated T cell epitope targets. Plasmodium falciparum is the most prevalent malaria parasite affecting humans in Africa, whereas Plasmodium vivax is more widespread and is the main species that causes malaria in the Americas and Asia1. P. vivax exclusively infects peripheral-blood reticulocytes, which retain RNA and the capacity for host protein synthesis2. We previously reported that reticulocytes infected with P.
Open in Who Shared Issue with article?
See all 580 licensed articles (599 Total)